Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines for patients.

Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, Flare’s team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target ‘switch sites’ has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.

Eventide

Boxer Capital

Casdin Capital

Nextech Invest

Invus

Third Rock Ventures

Flare Therapeutics

May is Bladder Cancer Awareness Month. To help raise awareness and honor those who have been impacted by the disease, the Flare team participated in the Bladder Cancer Advocacy Network's Boston Walk to End Bladder Cancer this past weekend. Thank you to our friends at BCAN for organizing a great event and for recognizing Flare with an award for the largest team, with more than 20 walkers. #bladdercancermonth23

We are excited to share that Flare Therapeutics is one of Inc. Magazine's Best Workplaces of 2023! Trailblazing a path to the possible for patients while cultivating a positive and collaborative work environment is part of what makes Flare so special. We are honored to be recognized. Check us out! flaretx.com #IncBestWorkplaces

The Flare team traveled to the recent #aacr2023 annual meeting in Orlando, Florida, putting FX-909 on full display with not one but two presentations from Jennifer Mertz, VP, Biology, shown below in front of a poster of our first preclinical data for FX-909, and CSO Robert Sims, shown presenting Flare's discovery of this first-in-class inhibitor of the #pparg transcription factor to potentially treat individuals with advanced urothelial cancer. Way to go, team! https://lnkd.in/eUB7ETQs

Flare continues to grow, and we're not stopping! We are glad to welcome Phuong Anh (Ani) Nguyen, Jon Goldstein, Blanche Carroll, and Mike Aguiar as the newest members of our team. To see other open roles at Flare, please visit flaretx.com/join-us/ #bringyourflare #team

This week, Flare Therapeutics announced the fantastic news that Michael Meyers has been appointed Chief Medical Officer, Daphne Karydas has been promoted to President, and Michaela Bowden has been promoted to Chief Development Officer. “Our commitment to strengthening our team reflects the tremendous progress we have made to date and the pivotal year ahead of us as we transition into a clinical-stage company,” said CEO Amit Rakhit, MD, MBA. #bringyourflare

https://lnkd.in/e-XttY_p

The Flare team is honored to announce our oversubscribed Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures LLC, with participation from a world-class group of existing and new investors. Proceeds from our financing will #illuminatethepath to a clinical trial in 2023 for FX-909, a small molecule inhibitor targeting the PPARG transcription factor, in patients with advanced #urothelialcancer, as well as the advancement of a pipeline of novel transcription factor targets in oncology, including nomination of at least one additional development candidate from the company’s research pipeline in 2024.
 
We are immensely grateful to the Flare team for continuing to trailblaze a path to the possible for science and patients. Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines. #seriesbfinancing #lifescienceinvestment #transcriptionfactors #pparg #oncology

Agent Capital Boxer Capital, LLC Casdin Capital, LLC Eli Lilly and Company Eventide Asset Management INVUS FINANCIAL ADVISORS, LLC Memorial Sloan Kettering Cancer Center Nextech Invest Novartis Pavilion Capital ShangBay Capital Third Rock Ventures

https://lnkd.in/ehBZiizY

This Thursday, Daphne Karydas, Flare CFO and COO, will give a company overview and answer questions at the 34th Annual @PiperSandler Healthcare Conference in New York. If you are attending, join her at 9:30am ET on December 1st. #PSCHealthcare2022

Check out this excellent story in Precision Oncology News profiling Flare Therapeutics' work building a potential new approach to targeting and treating advanced #urothelialcancers by inhibiting the #transcriptionfactor #PPARG. Robert Sims and Michaela Bowden spoke with Catherine Shaffer about the significance of our preclinical and translational research, as well as plans to enter the clinic in 2023. Read the story here: https://lnkd.in/eEEme8zm
#OneFlare #CancerResearch
#PrecisionOncology #IlluminatethePath

Over the past few months, we have added quite a few new sparks to flame our collective fire. We are certainly shining brightly as we look toward 2023. To Dave Lanzetta Melissa Moles Jeremy Setser Ana Rivas Stefan Kirov Serena Lunardi Jennifer Tepper Esin Tosun, welcome to Flare! #bebrilliant #oneflare

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

HSTS

Google Font API

Google Analytics

Content Delivery Network

Chief Medical Officer

Adrian Jubb

SVP, Biology & Translation

Michaela Bowden

Vice President, Finance

Robert Holman

Vice President, Computational Biology

Stefan Kirov

Senior Director Translational Bioinformatics and Biostatistics

Adarsh Joshi

Senior Director, People Experience

Ali Baker

Senior Director, Program Management and Operations

Dave Lanzetta

Associate Director, Operations and Program Management

Dylan Ciolfi

Finance and Administration

Esin Tosun

Senior Director, Translational Medicine, Oncology

Evisa Gjini-Bood, PhD, MBA

Abbie Celniker

Craig Gordon

Jakob Loven

Irena Melnikova

Stephen Frye

Lorence Kim

Aaron Davis

Jigar Raythatha

Jeanette W. Kohlbrenner

Interim Chief People Officer

Doug Manion

Chief Executive Officer

Fraydoon Rastinejad

Founder

Steven McKnight

Daphne Karydas

COO & CFO

Interim Chief Operating Officer

Mitchell Lazar

Agent Capital Portfolio Companies

East Coast Companies With Less Than $10M in Revenue (Top 10K)

East Coast Early Stage Companies With Fewer Than 100 Employees

United States Early Stage Companies With Less Than $50M in Revenue

Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. 

Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.

GordonMD Global Investments

Pfizer Venture Investments

Series B - Flare Therapeutics

Series A - Flare Therapeutics

Treatment and Processing of Materials Services

Cambridge

Massachusetts

United States

North America

Roche powers Flare’s tilt at cancer

Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology

Flare Therapeutics to Present at Two Upcoming November Conferences

Flare Therapeutics’ Post

Flare Therapeutics on LinkedIn: #bladdercancerawarenessmonth #liftthetorch #transcriptionfactors #biotech

Flare Therapeutics appoints Douglas Manion as CEO

Flare Therapeutics Names New CEO

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

A first-in-class small molecule inhibitor of the transcription factor PPARG, currently in Phase 1 clinical trials for advanced solid malignancies, including advanced urothelial carcinoma.

A platform that integrates genetic, biochemical, and chemical insights to identify druggable pockets in transcription factors, facilitating the development of small molecule modulators.

A collection of drug discovery programs targeting transcription factors with genetic and biological validation, initially focused on precision oncology and expanding to other areas like metabolic, neurology, immunology/inflammation, and rare genetic disorders.

A process guided by genetics, chemoproteomics, and structural biology to identify novel druggable pockets within transcription factor complexes.

An approach using cooperative biochemical systems and hit-finding technologies to assess the potential of identified switch sites to bind with small molecules.

The use of transcriptomic and epigenomic technologies to relate biochemical read-outs to cellular contexts, confirming assay validity and optimizing pharmacology for new TF-targeted medicines.

Philippines

Asia

India

Palestinian Territory

Flare Therapeutics is a biotechnology research company based in Cambridge, MA. They are trailblazing the path to target transcription factors and discover precision medicines for cancer and other disease areas. Their unique approach involves deciphering the biology of transcription factors by focusing on 'switch sites' as druggable regions that control predictable and profound changes in DNA transcription and gene expression. They have a pipeline of drug programs initially focused on precision oncology.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	3b5bc9ef
crunchbase profile	general	Nov 25, 2024 12:03 PM	7354f6e8
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 1:57 PM	d0d718ae
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:FLARETX

Flare Therapeutics